Scancell drug receives positive write-up in leading journal as company updates on survival data Immuno-therapy SCIB1, which is expected to progress into Phase II clinical trials in the second-half of the year, was the focus of a peer-reviewed paper in OncoImmunology [View article] Monday 12 February 2018 16:50 Categories: Media Coverage SCIB1 Year - 2018 Previous Post << >> Next Post